Biotech QMS Strategy: Transitioning from Excel to eQMS

Early-stage biotechnology companies face a demanding dilemma: how to enforce robust quality practices while remaining agile and resource-efficient. In practice, many small biotechs initially rely on DIY quality systems built around spreadsheets and shared drives (e.g. Microsoft Excel and SharePoint) because these tools are familiar, low-cost, and easy to deploy. The transition decision should assess the configured system and its intended use rather than assume that general-purpose software has no document controls. SharePoint in Microsoft 365 enables versioning automatically for new libraries and lists (^[1]). For regulated records, assess configuration, procedures, retention, access, and assurance evidence against the applicable requirements (^[2]).

This report provides a deep analysis of the timing and rationale for transitioning from simple tools to formal QMS in early-stage biotechs. Key findings include:

• Regulatory expectations: Determine which records and activities are regulated before selecting controls. FDA recommends documenting whether specific records fall within Part 11; its guidance describes enforcement discretion for specified provisions without waiving applicable predicate rules (^[2]). For medical-device manufacturers, the QMSR became effective on February 2, 2026 and incorporates ISO 13485:2016 by reference (^[3]). Do not treat device requirements as a blanket rule for all biotech research.

• Business and strategic drivers: Investors, partners, and auditors increasingly expect robust quality oversight. A formal QMS signals credibility and reduces due-diligence risk (^[4]). Assess software costs alongside the work needed to operate and maintain the quality system.

• Transition criteria: Plan around regulated activities, upcoming submissions, document and event volume, outsourcing, and process complexity. Set an implementation schedule that leaves time for configuration, assurance, training, and migration. Do not use a universal employee threshold or equate therapeutic-biotech pre-IND development with a fixed interval before commercialization.

• Benefits of dedicated QMS: Evaluate document control, CAPA (Corrective/Preventive Action), training, and risk-management workflows against the organization's requirements. Vendor evidence can support customer assurance; it is not a guarantee of compliance. Qualio describes validation as a partnership between vendor and customer (^[5]). Require an attributable case and a defined baseline before assigning a percentage improvement to any workflow.

This comprehensive report details the historical context, regulatory requirements, and operational considerations of DIY QMS, and provides a roadmap for small biotechs to plan their quality system evolution. We compare common QMS tools in tabular form, distinguish documented vendor reports from hypothetical planning examples, and explore future directions to support decisions about moving from Excel and SharePoint to an eQMS.

A Quality Management System (QMS) is the structured framework of policies, processes, and procedures that an organization uses to ensure consistent product quality, regulatory compliance, and continuous improvement (^[6]) (^[7]). In biotechnology – where companies develop drugs, biologics, or medical devices – a QMS must span research, clinical trials, and manufacturing. It typically covers document control (SOPs, protocols), training records, deviation/nonconformance management, change control, risk management (risk registers, FMEAs), supplier/vendor control, and CAPA tracking. Identify applicable requirements by product and activity, and document the electronic-record scope using FDA’s Part 11 guidance.

For early-stage biotech startups, quality challenges are both technical and cultural. Initially, teams focus on rapid R&D and analysis. Formal QMS tasks (writing SOPs, documenting processes) may seem burdensome. Many startups default to ad hoc approaches: storing documents in generic cloud folders (e.g. SharePoint) and tracking issues or training with Excel spreadsheets (^[8]) (^[9]). These “DIY” systems feel agile and cost-free, but they lack purpose-built compliance controls. As a recent industry guide notes, a typical emerging biotech’s QMS often is “a chaotic cocktail of Excel spreadsheets, SharePoint folders, and sheer willpower” (^[9]).

Historically, quality management in life sciences evolved from paper-based systems in regulatory GMP (Good Manufacturing Practices) contexts. The current U.S. device framework is the QMSR, effective February 2, 2026, incorporating ISO 13485:2016 by reference (^[3]). Electronic-record controls depend on applicable predicate rules and the records relied on for regulated activities (^[2]).

In practice, small biotech teams should map responsibilities for internal and outsourced activities, identify required records, and document the controls appropriate to those records. FDA recommends deciding and documenting which records are Part 11 records (^[2]).

The startup’s dilemma is to find a “just right” solution: sufficient for the applicable requirements and business processes, with a manageable implementation and operating burden. Compare the configured capabilities, supplier evidence, and total operating costs of each candidate. This report examines when and how an early-stage biotech should move from spreadsheets and generic file servers to an eQMS.

A quality system in biotech covers many domains. Critical components include:

• Document Control: Formal issuance and versioning of Standard Operating Procedures (SOPs), protocols, and quality manuals. Each controlled document must be reviewed and approved before use, with archived superseded versions.
• Training Management: Tracking employee training on SOPs, policies, and technical skills. Operations must ensure personnel are qualified (via training records) to perform regulated tasks.
• Deviation and CAPA Management: Logging any deviations, nonconformances or product complaints; analyzing root causes; and implementing corrective and preventive actions. CAPA workflows ensure issues are investigated, fixed, and prevented.
• Change Control: Managing changes to processes, equipment, or procedures. Any change must be reviewed, risk-assessed, and approved to prevent unintended quality impacts.
• Risk Management: Formal processes (e.g. FMEA, risk registers) to assess and mitigate risks to product quality or patient safety. Increasingly required under ICH Q9 and regulatory filings.
• Vendor/Supplier Control: Qualification and oversight of third-party partners (CROs, CDMOs, raw material suppliers). This includes audits of vendors and documentation of quality agreements.
• Audit Management: Planning and documenting internal and external audits (including regulatory inspections), tracking findings and follow-up plans.
• Integrated Data Integrity: Define attribution, record accuracy, review, retention, and access procedures for the records in scope. Select technical and procedural controls through a documented assessment rather than require one architecture for every experiment.

Regulatory scope: Separate the following activities when planning computerized-system controls:

• Discovery research and GLP: FDA's definition of a nonclinical laboratory study excludes basic exploratory studies and clinical studies. Do not classify every discovery experiment as a GLP study (^[10]).
• Clinical activities: Assess the applicable clinical requirements and the records relied on to perform regulated activities; document whether those records fall within Part 11 (^[2]).
• Drug GMP: Determine the manufacturing requirements applicable to the product and development phase. Qualifying Phase 1 investigational drugs are exempt from Part 211 under 21 CFR 210.2(c), while statutory CGMP obligations remain (^[11]).
• Medical devices: The QMSR is effective and incorporates ISO 13485:2016. Use its applicable incorporated requirements and FDA's current software-assurance guidance for production and QMS software; former 21 CFR 820.70(i) is a historical QSR reference (^[3]; February 2026 software-assurance guidance).
• EU GMP computerized systems: Annex 11 applies to computerized systems used as part of GMP-regulated activities and uses a documented risk assessment to determine validation and data-integrity controls (^[12]).

FDA's Part 11 guidance describes enforcement discretion for specified validation, audit-trail, retention, and copying provisions. Part 11 remains in effect, and applicable predicate-rule obligations remain enforceable (^[2]). Distinguish a useful change history from the audit-trail, record-retention, review, and security controls needed for the particular regulated record.

Investor and Partner Expectations: In addition to regulators, investors and industry partners (CROs, large pharma collaborators) test startups for “quality maturity.” Many biotech funders now include diligence on QA/QC processes. A formal QMS – even a lean one – signals that a company values data integrity and patient safety, potentially accelerating partnerships or funding (^[4]).

Plan a quality system around the applicable activities and records. The software decision should follow this scope assessment and the organization's operational needs.

Many early-stage biotechs default to DIY quality tracking. The typical configuration is:

• Document Storage: Digital files (SOPs, protocols, reports) saved in a folder hierarchy on SharePoint, Google Drive, or similar. Each document’s “final” version is often named with “_FINAL” or version notes in the filename.
• Spreadsheets as Trackers: Master Excel files serve as trackers. For instance, an Excel sheet may log SOP revisions and who is trained on them, or list CAPAs with status columns, or track equipment calibration dates and inspector signatures.
• Email/manual workflows: Reviews and approvals happen via email or comment threads, not in a centralized system.

This combination has apparent advantages: these tools are ubiquitous in office environments, easy to repurpose, and impose no additional software cost. Biotech leaders report doing exactly this during discovery and preclinical research when no regulatory pressure is immediately present (^[8]) (^[9]).

However, multiple analyses have highlighted the hidden “compliance tax” of the DIY model. A recent biotech QMS guide describes the situation bluntly: the off-the-shelf backup system is “a patchwork of SharePoint, Excel, and Dropbox that feels agile but carries a heavy, hidden ‘compliance tax’” (^[13]). In other words, the workarounds needed to make generic tools behave like a QMS become burdensome once audit-ready controls are required. We will detail below the specific gaps and risks that emerge when biotechs try to run a regulated-quality system on spreadsheets and shared folders.

Compare the configured environment and its intended uses. For the Microsoft 365 examples below, specify the Excel clients in use and whether workbooks reside in OneDrive or SharePoint Online. Avoid applying these capabilities to every standalone workbook or on-premises deployment.

1. Intended Use and Software Assurance

For medical-device production and quality-management software, FDA recommends an approach proportionate to the risk associated with the software's use, consistent with the incorporated ISO 13485 requirements (^[14]). For other regulated records, determine the relevant predicate rules and Part 11 scope (^[2]).

Document the required functions, configuration, acceptance evidence, procedures, and responsibilities. Assess software changes for their impact on the approved intended use; do not assume that every update requires a complete repeat of validation. Apply this assessment to both Microsoft-based systems and dedicated eQMS products.

2. Change History and Audit-Trail Requirements

SharePoint version history can identify when a file or item changed and who changed it. Excel's Show Changes in supported Microsoft 365 clients can identify the editor, change, time, and prior cell value. These are native capabilities. Assess the required event coverage, retention, administrative permissions, review process, and record exports before relying on any change history for regulated records. Distinguish change history from an audit trail assessed for the specific regulated use.

3. Version Control and Document Release

SharePoint supports configurable content approval and required checkout. Required checkout and simultaneous co-authoring represent different ways of managing edits; select the approach appropriate to the workflow. Define the current approved version, visibility of drafts, archive and retention rules, and treatment of exported copies. Test these controls and train users on the document-release procedure.

4. Data Entry Rules and Calculation Assurance

Excel provides native data-validation rules, input messages, and error alerts (^[15]). These cell-entry rules are different from assurance that software and its configured calculations are fit for an intended regulated use. Microsoft notes that validation messages do not appear when values are copied or filled, so test the actual entry and import workflow.

Define controlled templates, field types, units, permissible values, and checks for critical calculations. Assign ownership for formulas and assess changes before release. Do not use a general spreadsheet-error percentage or a genetics-paper sample to predict performance of a biotech QMS.

5. Collaboration and Access Governance

Supported Excel clients can co-author workbooks stored in OneDrive or SharePoint Online. SharePoint provides permission levels and configurable approval processes. Define who may view, edit, approve, administer, and share records; test the configured permissions against those responsibilities. Establish individual accountability, access-review procedures, and a controlled route for approvals. Evaluate the same requirements when selecting a dedicated eQMS.

6. Reporting, Analytics, and Traceability

Evaluate the intended reporting functions and data flows rather than assume that reporting or traceability is impossible in general-purpose tools. For device production and QMS software, FDA recommends examining the intended uses of individual features, functions, and operations when developing the assurance strategy (^[14]).

As a practical comparison, ask each proposed system to demonstrate an overdue-training report, an open-CAPA report, and a document-change record linked to its affected processes. Define reconciliation and review steps for information transferred between systems. Use these demonstrations to estimate the recurring administration and integration work.

The decision is whether the configured system, procedures, and supporting evidence meet the applicable requirements at an acceptable operating cost. Neither the Microsoft product names nor an eQMS label alone resolves that question.

A dedicated electronic QMS (eQMS) is an option for coordinating document control, quality events, and training as operational needs grow. Evaluate the following functions against specific user requirements rather than treat product selection as compliance assurance.

• Electronic-record controls: Evaluate the identity, approval, signature, audit-history, retention, and export functions required for the records in scope. Confirm their configured behavior and document the procedures governing their use (^[2]).

• Integrated Workflows and Automation: A QMS offers digital forms and workflows for each quality process. Instead of emailing spreadsheets, one “submit and track” interface can automatically notify reviewers, escalate overdue tasks, and route CAPAs. As QT9 Software describes, a QMS can auto-trigger corrective actions, assign tasks, and send reminders at each stage (^[16]). These workflows greatly reduce administrative overhead. For instance, when a nonconformance is reported, the QMS might automatically create an investigation record, schedule a review meeting, and document the root cause analysis. In a spreadsheet model, each of these steps would require manual coordination and data entry, with high risk of oversight.

• Centralized Data and Visibility: Document management, training records, and quality events should be evaluated together. In a demonstration, request cross-process queries such as “show all users with outstanding training for SOP 5.3” or “list open CAPAs without due dates.” Establish what the platform includes and what requires integration; measure any claimed reduction in data-handling effort against the actual workflow.

• Validation and Reliability: Treat vendor testing and documentation as evidence to assess against customer requirements. FDA’s device software-assurance guidance describes using activities performed by developers, suppliers, and cloud providers within a risk-based approach (^[14]). Establish customer acceptance, configuration control, supplier oversight, change assessment, and procedures for the intended use.

• Scalability and Support: Evaluate additional users, sites, modules, interfaces, and record volumes during selection. Define hosting, maintenance, incident response, and release-notification responsibilities in the supplier agreement. Budget for training, change assessment, and continuing customer oversight.

• Performance Evidence: Request attributable customer cases with the process measured, starting baseline, intervention, measurement period, and limitations. Treat illustrative or anonymized vendor testimonials as marketing examples, not independently established evidence of CAPA or deviation-closure improvement.

These functions come with trade-offs in subscriptions, training, setup, and ongoing administration. Compare their demonstrated value with the costs of operating the current configured system.

This comparison assumes supported Microsoft 365 Excel clients with workbooks in OneDrive or SharePoint Online and configured SharePoint libraries. Check the specific versions, licenses, configuration, and intended use. The eQMS column lists capabilities to verify, rather than guarantees common to every product.

Capability / Requirement	Excel + SharePoint	Purpose-Built eQMS: What to Verify
Document Control & Versioning	Native SharePoint versioning, content approval, and configurable required checkout; define draft visibility and release procedures.	Demonstrate controlled revision, approval, effective versions, and retrieval of superseded records.
Audit Trail	SharePoint version history includes editor identity; supported Excel Show Changes provides recent cell-change details. Assess coverage, retention, administrative access, review, and exports for the records in scope.	Demonstrate relevant event capture, user attribution, protection, retention, review, and reconstruction of record changes.
Electronic Signatures	Assess the configured signing solution and its association with the record, identity, and procedures; version history alone is not a signature.	Demonstrate the required signature meaning, identity checks, record linkage, and evidence of the configured behavior.
CAPA and Deviation Management	Define register structure, owners, investigation links, review, due dates, and closure controls.	Demonstrate event routing, investigation, reminders, approval, effectiveness checks, and reporting.
Training Management	Define the training matrix, evidence, assignment process, and handling of revised SOPs.	Demonstrate assignment, completion records, reminders, and retraining on relevant changes.
Access Control & Security	SharePoint provides permission levels; assess view, edit, approval, sharing, and administration rights for the intended workflow.	Test roles and administrator powers, authentication, sharing, and removal of access against approved requirements.
Regulatory Compliance Support	Assess the configured system, procedures, record controls, and assurance evidence against applicable requirements.	Apply the same assessment; vendor features and documentation support customer assurance rather than guarantee compliance.
Collaboration & Visibility	Supported Excel clients allow co-authoring in the supported cloud configuration; choose checkout or co-authoring as appropriate.	Demonstrate simultaneous access, notifications, controlled review, and clear ownership of tasks.
Scalability & Maintenance	Define administration, template maintenance, storage, interfaces, and change assessment as usage expands.	Define provider maintenance and release responsibilities alongside customer assessment, acceptance, and oversight.
Implementation Time & Cost	Include configuration, assurance, procedures, training, integrations, and recurring administration.	Include licenses, configuration, migration, assurance, training, interfaces, and continuing oversight; obtain a scoped schedule.
Data Integrity & Analytics	Excel supports input-validation rules; test formulas, imports, critical checks, and report reconciliation.	Test configured fields, calculations, data transfers, and reports; substantiate any claimed analytics benefit.
Risk Management	Define a maintained risk register and links to the activities and controls it informs.	Demonstrate risk assessment, ownership, review, and linkage to relevant changes and events.
Audit Readiness	Test whether required records and their context can be retrieved accurately for the applicable retention period.	Test the same retrieval and completeness requirements; do not assume a report button establishes readiness.

Table 1. Comparison of quality-management controls and evaluation tasks. Microsoft documents native versioning, approval, checkout, permissions, change history, co-authoring, and cell validation (^[1]; checkout; permissions; change history; co-authoring; cell validation). Assess both approaches for the actual regulated records and intended uses (^[2]; FDA device software-assurance guidance).

Determining the right time to transition depends on a biotech’s stage, scale, and risk profile. Use the following operational triggers to assess whether the current configured system remains suitable.

• Approaching Regulatory Milestones: If the company plans to file an IND, CTA, or enter formal clinical trials, compliance demands surge (^[17]). Major filings require documentation (SOPs, batch records, validation reports) that must be traceable and reliable. Proactively implementing a QMS before the first audit or filing is prudent: as one expert notes, retrofitting a QMS under inspection pressure is far more costly than building it early (^[18]).

• Quality Event Volume: A few deviations or CAPAs can often be handled in a simple spreadsheet. But as the number increases (for instance, clinical site issues or multiple preclinical failures), tracking them manually becomes untenable. If management finds it difficult to see the status of open issues at a glance, it’s time for an automated CAPA module.

• Team Size and Complexity: Assess the number of functions, sites, partners, records, and handoffs involved. Use missed approvals, reconciliation effort, overdue training, and quality-event workload as planning inputs. Do not use an unverified employee-count threshold.

• Vendor and CRO Engagement: Most biotechs outsource lab testing or manufacturing. Regulatory agencies expect sponsors to manage and oversee external partners as if the work were done in-house (^[19]). This includes supplier qualification, contract auditing, and integration of third-party records. Handling outsourced data via spreadsheets is very difficult: for instance, consolidating audit reports stored on a CRO’s server vs supply logs in another spreadsheet is error-prone. A unified QMS can attach supplier documents and CAPAs directly to vendor profiles. Thus, increased reliance on CROs/CDMOs is a strong reason to deploy formal QMS tools (^[19]).

• Investors and Partnerships: Strategic partners (large pharma licensors, investors) often ask for evidence of a working quality system during due diligence (^[4]). An empty promise of “we use Excel” will not reassure them. A visible, auditable QMS signals lower risk, expedite negotiations, and can even be a competitive advantage in partnerships.

• Regulatory or Market Requirements: Identify applicable MDR/IVDR quality-system obligations and any certification required by the business or customers. Harmonised standards are voluntary and confer a presumption of conformity for the requirements they cover when their references are published in the EU Official Journal (^[20]). Do not present ISO 13485 certification as a blanket EU legal requirement. IVDR has applied since May 26, 2022, with transition periods for eligible devices subject to the applicable conditions (^[21]).

Timing in the Development Cycle: Schedule the quality-system work around the regulated activities to be undertaken and allow time for assurance, migration, and training. For this article’s therapeutic-biotech planning, use product-specific milestones, complexity, and risk rather than a fixed commercialization countdown.

Use a phased QMS roll-out matched to business needs: begin with document control, training, and basic change control, then expand processes as the regulated activities and operational workload change.

• Alphazyme — vendor-reported case study: Qualio reports that Alphazyme implemented its eQMS when the company initiated its first R&D experiments (^[22]). This documents an early implementation; it does not establish an IND deadline, a CTO decision, or a measured reduction in SOP turnaround time.

• Unnamed hypothetical planning scenario: Consider a biotech coordinating several external partners and protocols. Before selecting a system, define how it will link approved procedures, training, quality events, and supplier records. Use a pilot to test retrieval, permissions, and reconciliation. This is a proposed evaluation scenario with no observed performance or inspection outcome attributed to any company.

Use documented cases to understand implementation choices, and keep hypothetical planning exercises separate from measured outcomes. The following table lists operational prompts for evaluating a transition.

Trigger / Condition	Rationale and Impact	Example / Source
Regulatory filing or audit imminent	Identify the required records and test their completeness, traceability, and retrieval before the milestone.	Product-specific submission, internal audit, or external assessment.
Multiple active documents/versions	Difficulty tracking current SOPs or batch records. High risk of using wrong versions.	Center of a review meeting and realize several “final” SOPs exist for same process.
Increasing process complexity	Review whether coordination, approvals, and record reconciliation remain manageable.	Multiple functions, sites, products, or outsourcing partners; no universal headcount cutoff.
Spikes in deviations or CAPAs	Volume of quality events overwhelms spreadsheets; delay in closure could harm timelines.	QC rejects double, CAPAs slip past review due to Excel backlog.
Outsourcing/R&D expansion	Managing CROs/CDMOs demands supplier oversight. Contract research success depends on sponsor’s quality control.	A biotech with multiple CROs needs formal vendor qual.
Investor/CXO scrutiny	Due diligence or partnership requires demonstration of quality oversight; spreadsheets signal risk.	Venture reviews, partnership audits ([4]).
Compliance backlog or findings	Past quality findings, or traceability issues discovered, often prompt system overhaul.	After an internal audit finds missing training records.
Introduction of formal risk processes	Implementing ISO 14971/ICH Q9 risk management or design controls in medTech triggers need for linked QMS processes.	Beginning product lifecycle risk assessments.

Table 2. Common planning criteria for assessing a QMS transition. These are decision prompts, not legal employee thresholds or universal deadlines.

When a company decides to move to a formal QMS, a phased approach is often recommended (^[23]). Key steps include:

1. Core Controls (Document Management & Training): Begin by establishing a single, digital source of truth for SOPs, protocols, and training records. This addresses the most immediate risks of version confusion and untrained staff. Montrium experts call “document control + training” the foundation phase for any startup’s QMS (^[23]). Even a basic eQMS module here (SOP repository with revision history, and automated training assignments) can yield outsized benefits: it stops the widespread habit of “which version is current? Did everyone get trained?” as one consultant noted (^[23]).

2. Quality Event Management: Next, deploy corrective action and nonconformance modules. Track any deviations formally, with workflows for investigation and CAPA. This may also include early risk management tools (to log and score issues). Configure investigation, review, and closure responsibilities, and confirm that the workflow supports the applicable requirements.

3. Change Control & Supplier Management: As the product development matures, systematize change control. Anytime a process or design is altered, the QMS should route the change request to affected stakeholders (QA, manufacturing, regulatory). The QMS can maintain a digital change order history linked to impacted documents. Similarly, implement basic vendor qualification (supplier lists, audit records) as outsourcing grows. This step is often triggered when the number of third-party partners becomes large enough to risk quality oversight gaps.

4. Full Enterprise Quality: In the final phase (often coinciding with late clinical or commercial scale-up), roll out the remaining modules: comprehensive risk management, audit management, complaint handling, and advanced analytics. By this stage the goal is an end-to-end system: trial master file linkage, electronic batch records, or any region-specific requirements.

At each phase, assess the intended use and risks of new functions, document the necessary assurance evidence, and update procedures for the approved digital workflow. Involve end-users early and provide training before release (^[14]).

Migration and Cutover Checklist

Use this checklist as a planning aid; tailor its scope and acceptance criteria to the records and activities being migrated.

1. Inventory and ownership: List Excel workbooks, SharePoint libraries, controlled documents, training records, quality events, and interfaces. Assign an owner and identify authoritative versions, duplicates, retention requirements, and records that will remain archived.
2. Mapping and reconciliation: Map fields, identifiers, units, statuses, relationships, and attachments to the destination. Perform a trial migration; reconcile record counts and critical values, investigate differences, and approve the results.
3. Provenance and historical records: Preserve source identifiers, dates, approvals, and available history. Document mappings and transformations. Retain retrievable source records where the destination cannot represent their history; do not invent retrospective audit events.
4. Access and user acceptance: Test view, edit, approval, export, and administrator permissions. Have users test representative workflows, record retrieval, and critical calculations against agreed acceptance criteria. Resolve or formally assess open issues before acceptance.
5. Cutover: Approve a final migration plan, freeze legacy editing at the agreed time, reconcile the final transfer, define a rollback decision, and designate the authoritative system. Train users and issue the updated procedures.
6. Post-launch monitoring: Review failed transfers, access issues, overdue tasks, and retrieval problems. Assign owners for corrective work and confirm that historical records remain accessible for their required retention period.

For GMP-scoped migrations, Annex 11 calls for checks that transferred data retain their value and meaning (^[12]).

Buy vs. Build: Software Selection

A fundamental choice is whether to build an in-house QMS framework or buy a commercial eQMS. Compare both against the intended processes, controls, staffing, and continuing assurance work. Do not assume that a previous customer's supplier audit establishes acceptance for a new customer's configuration.

FDA's device software-assurance guidance allows supplier and developer activities to contribute to an assurance strategy, while requiring a proportionate approach to the actual intended use (^[14]). Evaluate the relevance of vendor evidence, determine any additional customer activities, and document acceptance. Define responsibility for configuration, procedures, supplier oversight, change assessment, and records.

Aspect	Build: Planning Questions	Buy: Planning Questions
Implementation Cost	Who will specify, develop, configure, test, document, and support the system? Include internal labor and interfaces.	Include licenses, configuration, migration, assurance, training, interfaces, and recurring administration.
Time to Launch	Obtain a scoped schedule for development, acceptance, migration, and release.	Obtain a scoped schedule and confirm customer dependencies; do not infer a universal deployment duration.
Regulatory Readiness	Define and demonstrate controls for the applicable requirements.	Assess vendor controls and evidence against customer requirements and configured workflows.
Maintenance & Support	Assign ownership for defects, releases, security, and continued suitability.	Establish provider responsibilities, notifications, support, and customer change assessment.
Scalability	Test the expected records, users, sites, and interfaces.	Demonstrate capacity, contractual limits, exports, and the effort to add functions or sites.
Selection Criteria	Assess whether distinct requirements justify the development and lifecycle burden.	Assess whether an available configuration meets requirements at an acceptable total cost.

Table 3. Build and buy evaluation questions. Neither route guarantees compliance or savings. Select the approach supported by requirements, evidence, staffing, and a documented operating model.

Grand View Research identifies technological advances and regulatory needs as drivers of the life-sciences quality-management software market (^[24]). A publisher's market estimate describes demand; it does not establish the benefit, compliance status, or return on investment of a particular implementation.

For this decision, collect evidence about the processes the organization actually intends to change. Establish a baseline for document review, training completion, quality-event closure, record retrieval, and reconciliation effort. Record the implementation scope and measurement period before comparing results.

Require attributable evidence before publishing numerical improvements. Do not transfer data-collection or cleaning results from a lab platform to eQMS document production, IND preparation, CAPA closure, or clinical-development timelines. Evaluate any proposed AI function separately for its intended use and the controls needed to rely on its outputs.

Quality management technologies continue to evolve, and forward-looking biotech companies should be aware of upcoming trends:

• Advanced Analytics and Machine Learning: Beyond static record-keeping, QMS platforms are beginning to include analytics engines. These can correlate diverse quality metrics (e.g. linking supplier performance with CAPA frequency) and provide early-warning dashboards. In the near future, AI-driven risk flattening (predictive CAPAs, anomaly detection in manufacturing data) will further set apart next-gen QMS from legacy systems (^[25]) (^[26]).

• Integration with Lab and ERP Systems: For a truly unified operational view, QMS are moving toward integration with other life-science systems. The best-of-breed approach envisions linking QMS with Laboratory Information Management Systems (LIMS), Electronic Lab Notebooks (ELN), Product Lifecycle Management (PLM), and ERP. For example, a reagent batch number from LIMS might automatically populate a production record in the QMS; or a lab safety incident logged in one system could auto-notify QMS workflows. ComplianceQuest and others emphasize “end-to-end” integration with health of manufacturing and R&D processes (^[27]). Such integration is challenging but will likely become standard, moving quality from an isolated module to a pervasive enterprise function.

• Cloud and Mobile Adoption: The pandemic-driven shift to remote work accelerated cloud acceptance. Today's teams expect to access QMS from any device (office, home, factory floor). Mobile interfaces for QMS allow managers to approve documents or sign operations from tablets, increasing responsiveness. Security (multi-factor authentication, encryption at rest) is a continual focus to keep cloud systems audit-ready.

• Regulatory Evolution: Track published rules and guidance relevant to the product and activities. For device production and QMS software, use the current QMSR and FDA’s February 2026 software-assurance guidance (^[3]; software assurance). Do not infer future requirements for all R&D records from general regulatory interest in digital systems.

• Record Architecture: Assess any proposed immutable-record technology against the actual requirements for attribution, correction, retrieval, retention, and controlled access. Request evidence of suitability for the intended process before selecting an architecture.

• Culture of Quality: Ultimately, technology supports but does not create a quality culture. As one Montrium blog put it, leadership must own quality, or else even the best QMS can languish (^[28]). The future of QMS will also involve embedding quality thinking across R&D teams. Tools alone are insufficient if staff are not trained, engaged, and empowered to use them. Top biotech companies now actively train scientists on QMS processes early, and involve quality personnel in cross-functional projects. In this way, the evolution from spreadsheets to software also accompanies a shift toward proactive quality leadership.

Early-stage biotech companies should reassess their quality-management tools as regulated activities and operational complexity increase. Make the transition decision using applicable requirements, the current configured controls, demonstrable workflow needs, and the cost of continuing to operate each option.

Use a phased and risk-based implementation: establish document control and training, then add process controls as the activities require them. Complete assurance, migration reconciliation, user acceptance, and training before cutover, and monitor the system after release. Vendor evidence can support assurance, while customer assessment and acceptance remain necessary (^[14]).

Quality-system effectiveness depends on defined responsibilities, usable workflows, and evidence that the configured system performs as intended. Assess the intended uses and associated risks throughout its life cycle rather than rely on a software category as a promise of compliance.

Source context: Regulatory statements above cite FDA and European Commission materials; product-capability statements cite Microsoft documentation. The retained company example is explicitly attributed to the vendor’s case study. Vendor commentary and market estimates should be read within their stated scope, and the hypothetical planning scenario is not evidence of observed results.